Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
Fernando Bril, Srilaxmi Kalavalapalli, Virginia Clark, et al.
Clinical Gastroenterology and Hepatology (2017) Vol. 16, Iss. 4, pp. 558-566.e2
Closed Access | Times Cited: 181

Showing 1-25 of 181 citing articles:

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 731
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 371
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels
Molecular Metabolism (2020) Vol. 42, pp. 101092-101092
Open Access | Times Cited: 361
Targeting metabolic dysregulation for fibrosis therapy
Xiao Zhao, Jennifer Kwan, Kenneth W. Yip, et al.
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 1, pp. 57-75
Closed Access | Times Cited: 356
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 348
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Fernando Bril, Diane Biernacki, Srilaxmi Kalavalapalli, et al.
Diabetes Care (2019) Vol. 42, Iss. 8, pp. 1481-1488
Open Access | Times Cited: 274
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 399-406
Open Access | Times Cited: 246
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 222
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 191
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, et al.
Clinical Science (2022) Vol. 136, Iss. 18, pp. 1347-1366
Open Access | Times Cited: 168
Therapeutic Landscape for NAFLD in 2020
Brent A. Neuschwander‐Tetri
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1984-1998.e3
Closed Access | Times Cited: 167
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 165
Current treatment of non‐alcoholic fatty liver disease
Rafael Paternostro, Michael Trauner
Journal of Internal Medicine (2022) Vol. 292, Iss. 2, pp. 190-204
Open Access | Times Cited: 156
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 144
Hepatic stellate cells in physiology and pathology
Dakota R. Kamm, Kyle S. McCommis
The Journal of Physiology (2022) Vol. 600, Iss. 8, pp. 1825-1837
Open Access | Times Cited: 140
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Eun Young Lee, Hannelie Korf, Antonio Vidal‐Puig
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 1048-1062
Open Access | Times Cited: 97
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 70
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies
Erica Vetrano, Luca Rinaldi, Andrea Mormone, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 468-468
Open Access | Times Cited: 41
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 27
Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review
L Konings, Lorena Miguelañez‐Matute, Anna M P Boeren, et al.
European Journal of Clinical Investigation (2025)
Open Access | Times Cited: 1
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Nahúm Méndez‐Sánchez, Vania Cruz-Ramón, Oscar Ramírez-Pérez, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 7, pp. 2034-2034
Open Access | Times Cited: 140
Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
Hannah K. Drescher, Sabine Weiskirchen, Ralf Weiskirchen
Cells (2019) Vol. 8, Iss. 8, pp. 845-845
Open Access | Times Cited: 118
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Anne Fougerat, Alexandra Montagner, Nicolas Loiseau, et al.
Cells (2020) Vol. 9, Iss. 7, pp. 1638-1638
Open Access | Times Cited: 112
Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease
Ze Chen, Yao Yu, Jingjing Cai, et al.
Trends in Endocrinology and Metabolism (2019) Vol. 30, Iss. 12, pp. 903-914
Closed Access | Times Cited: 104
Page 1 - Next Page

Scroll to top